What is Galvus Met?

Galvus met contains the active ingredient Vildagliptin in combination with Metformin, which is indicated in the treatment of type 2 diabetes. Let's learn about the uses and notes when using Galvus met through the article below.

"What is Galvus Met?". Galvus met contains the active ingredient Vildagliptin combined with Metformin, which is prepared in the form of vildagliptin/metformin hydrochloride ratios of 50mg/500mg, 50mg/850mg, 50mg/1000mg. The drug is indicated in the treatment of type 2 diabetes with the following specific uses:
Galvus met is indicated as an adjunct to diet and exercise to help improve blood sugar control in humans. type 2 diabetes mellitus with uncontrolled glycemic control with metformin hydrochloride, vildagliptin alone or in patients receiving combination therapy with metformin hydrochloride and vildagliptin tablets separately; Galvus met is indicated in combination with a sulfonylurea as an adjunct to diet and exercise in patients not adequately controlled by sulfonylurea and metformin; Galvus met is indicated in conjunction with insulin as an adjunct to diet and exercise to improve glycemic control in patients already receiving stable insulin and metformin for inadequate glycemic control. full.

The treatment regimen for type 2 diabetes depends on the individual patient and on the effectiveness of tolerability. Dosage recommendations for Galvus met are as follows:
The recommended starting dose is based on the patient's current regimen of vildagliptin and/or metformin hydrochloride. The drug should be taken with meals to help reduce gastrointestinal complications caused by metformin; Initial dose for patients on Vildagliptin monotherapy but with inadequate blood glucose control: Based on the usual starting dose of Metformin hydrochloride (850 mg once daily or 500 mg twice daily). Galvus met can be used initially with a 50mg/50mg tablet twice a day and gradually increased after assessing the adequacy of the treatment response; Starting dose in patients not controlled with metformin hydrochoric monotherapy: Based on the dose of metformin hydrochloric being treated in the patient, Galvus met may be initiated with a dose of 50 mg/500 mg. , 50mg/ 850mg or Galvus met 50mg/ 100mg twice a day; Initial dose in patients switching from a combination of vildagliptin and metformin hydrochloride alone: ​​The drug can be started at 50mg/500mg, 50mg/850mg or 50mg/1000mg depending on the dose of metformin or vildagliptin being used; When co-administering Galvus met with a sulphonylurea drug, consideration should be given to reducing the dose of the sulfonylurea drug in order to reduce the risk of excessive hypoglycaemia.

Some side effects that may be encountered when using Galvus met are as follows:
Common side effects: Diarrhea, nausea, vomiting, loss of appetite, headache, dizziness, tremor, taste of needles type. In addition, the patient may experience conditions such as fatigue, joint pain, swelling of the hands, constipation, swelling of the ankles or feet; Rare side effects: Runny nose, sore throat, fever, lactic acidosis (symptoms of dizziness or drowsiness, severe vomiting or nausea, abdominal pain, irregular heartbeat, deep and rapid breathing), itching, redness skin, vitamin B12 deficiency (symptoms of fatigue, pallor, psychiatric symptoms such as memory disturbances, confusion); When Galvus met is used in combination with a sulfonylurea, the patient may experience problems such as tremors, dizziness, excessive hypoglycemia, weakness, and excessive sweating. Patients should see a doctor immediately if they experience side effects such as lactic acidosis, angioedema, liver disease (hepatitis).

The use of Galvus met is contraindicated in the following cases:
People who are sensitive to any component of Galvus met; Patients with severe renal failure (GFR <30 ml/min); Diabetic coma patients; Patients with acute metabolic acidosis such as diabetic ketoacidosis, lactic acidosis; Patients with severe congestive heart failure need drug treatment; Patients with liver failure, chronic alcoholism, acute poisoning, lactating women, acute conditions that may alter renal function such as severe infection, dehydration, shock, intravenous contrast agents containing iodine, chronic diseases can lead to tissue hypoxia such as respiratory failure, heart failure, shock, new myocardial infarction.

Some notes when using Galvus met as follows:
Do not use Galvus met in the treatment of type 1 diabetes or the treatment of diabetic ketoacidosis. Perform liver function tests prior to treatment with Galvus met. These tests should be monitored and checked every 3 months during drug treatment. For patients with elevated transaminase levels, liver function should be re-evaluated a second time to confirm the results, then regularly re-evaluate liver function until the functions return to normal. In case the AST and ALT levels are increased to 3 times the upper limit of normal or are persistently increased, the patient should be discontinued treatment with Galvus met. The drug is not recommended for use in patients with liver failure, heart failure. Pregnant women: There are not enough scientific studies on the use of Galvus met in pregnant women. Embryo development studies conducted in rats with the combination vildagliptin/metformin in a ratio of 1:10 resulted in no teratogenic effects in laboratory rats. Despite this, Galvus met is not recommended in pregnant women unless the potential benefit outweighs the risk to the fetus. Lactation: Animal studies have shown that the drug is excreted in human milk. Because of the potential risk of neonatal hypoglycaemia associated with metformin and limited human data, Galvus Met should not be used in nursing women. Fertility: Animal studies have shown that vildagliptin does not cause impaired fertility or early embryonic development. In addition, the fertility of male and female rats was not affected by metformin administered at a high dose of 600 mg/kg/day, a dose approximately three times the maximum recommended human daily dose based on comparative results. body surface area comparison.

Metformin may interact with drugs containing active ingredients such as Nifedipine, Furosemide, Amilorid, Glyburid, Procainamide, Digoxin, Morphin, Quinidin, Ranitidine, Quinin, Trimethoprin, Triamteren or Vancomycin,...
No clinical evidence yet. on the interaction between vildagliptin and antidiabetic drugs of the same class (Pioglitazone, Glibenclamid, Metformin hydrochloride) and some other drugs such as Digoxin, Amlodipine, Simvastatin, Ramipril, Valsartan or Warfarin,...
Some drugs have a tendency to increased blood glucose levels when used together with Galvus met as Corticosteroids, Thiazide diuretics, Phenytoin, Phenothiazines, Estrogen, nicotinic acid, calcium channel blockers and Zoniazid, oral contraceptives. Blood glucose levels should be closely monitored and metformin dose adjusted or discontinued in these subjects.